HIGHLIGHTS
- who: B. G. Wortman from the (UNIVERSITY) have published the Article: Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy, in the Journal: (JOURNAL)
- how: The present analysis was done to analyse long-term outcomes of the PORTEC-2 trial and evaluate whether specific clinicopathologic and molecular risk factors can be used to determine optimal adjuvant treatment for subgroups at higher risk of recurrence. Both log-rank tests and Cox regression models were stratified for FIGO stage but were essentially the same with and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.